Ke Ding

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1517271/publications.pdf

Version: 2024-02-01

218 papers	9,714 citations	34016 52 h-index	48187 88 g-index
238 all docs	238 docs citations	238 times ranked	12516 citing authors

#	Article	IF	Citations
1	Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2â^'p53 Interaction. Journal of Medicinal Chemistry, 2006, 49, 3432-3435.	2.9	647
2	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3933-3938.	3.3	641
3	Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors. Journal of the American Chemical Society, 2005, 127, 10130-10131.	6.6	608
4	Antineoplastic Mechanisms of Niclosamide in Acute Myelogenous Leukemia Stem Cells: Inactivation of the NF-ÎºB Pathway and Generation of Reactive Oxygen Species. Cancer Research, 2010, 70, 2516-2527.	0.4	294
5	Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. Cell Chemical Biology, 2018, 25, 206-214.e11.	2.5	197
6	Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Medicinal Chemistry Letters, 2010, 1, 454-459.	1.3	196
7	Potent and Orally Active Small-Molecule Inhibitors of the MDM2â^'p53 Interaction. Journal of Medicinal Chemistry, 2009, 52, 7970-7973.	2.9	169
8	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nature Medicine, 2016, 22, 270-277.	15.2	150
9	Adipocyte Fatty Acid-binding Protein Modulates Inflammatory Responses in Macrophages through a Positive Feedback Loop Involving c-Jun NH2-terminal Kinases and Activator Protein-1. Journal of Biological Chemistry, 2010, 285, 10273-10280.	1.6	136
10	BMPs functionally replace Klf4 and support efficient reprogramming of mouse fibroblasts by Oct4 alone. Cell Research, 2011, 21, 205-212.	5.7	130
11	Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 3281-3295.	2.9	128
12	Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chinese Journal of Cancer, 2014, 33, 80-86.	4.9	128
13	Design, Synthesis, and in Vitro Biological Evaluation of 1H-1,2,3-Triazole-4-carboxamide Derivatives as New Anti-influenza A Agents Targeting Virus Nucleoprotein. Journal of Medicinal Chemistry, 2012, 55, 2144-2153.	2.9	125
14	Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Regionâ€“Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib. Journal of Medicinal Chemistry, 2013, 56, 879-894.	2.9	125
15	(2-Pyridyl)acetone-Promoted Cu-Catalyzed O-Arylation of Phenols with Aryl Iodides, Bromides, and Chlorides. Journal of Organic Chemistry, 2009, 74, 7187-7190.	1.7	116
16	Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chinese Journal of Cancer, 2012, 31, 178-184.	4.9	115
17	Targeting EGFR^{L858R/T790M} and EGFR^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal Research Reviews, 2018, 38, 1550-1581.	5.0	113
18	Magnetically engineered Cd-free quantum dots as dual-modality probes for fluorescence/magnetic resonance imaging of tumors. Biomaterials, 2014, 35, 1608-1617.	5.7	110

#	Article	IF	Citations
19	An Efficient Copperâ€Catalyzed Amination of Aryl Halides by Aqueous Ammonia. Advanced Synthesis and Catalysis, 2009, 351, 1722-1726.	2.1	109
20	New Promise and Opportunities for Allosteric Kinase Inhibitors. Angewandte Chemie - International Edition, 2020, 59, 13764-13776.	7.2	109
21	Palladiumâ€Catalyzed Amidation of Nâ€Tosylhydrazones with Isocyanides. Chemistry - A European Journal, 2011, 17, 12268-12271.	1.7	103
22	Copper-Catalyzed Desymmetric Intramolecular Ullmann Câ€“N Coupling: An Enantioselective Preparation of Indolines. Journal of the American Chemical Society, 2012, 134, 14326-14329.	6.6	97
23	2H-Azirine-Based Reagents for Chemoselective Bioconjugation at Carboxyl Residues Inside Live Cells. Journal of the American Chemical Society, 2020, 142, 6051-6059.	6.6	97
24	A CuAAC/Ullmann Câ€“C Coupling Tandem Reaction: Copper-Catalyzed Reactions of Organic Azides with N-(2-Iodoaryl)propiolamides or 2-Iodo-N-(prop-2-ynyl)benzenamines. Organic Letters, 2012, 14, 3332-3335.	2.4	96
25	Copper-Catalyzed Tandem Reactions of 1-(2-Iodoary)-2-yn-1-ones with Isocyanides for the Synthesis of 4-Oxo-indeno[1,2-b]pyrroles. Organic Letters, 2011, 13, 340-343.	2.4	91
26	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Molecular Cancer Therapeutics, 2008, 7, 1533-1542.	1.9	87
27	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2017, 16, 2473-2485.	1.9	86
28	Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics. Cell Research, 2011, 21, 884-894.	5.7	84
29	Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation. Journal of Medicinal Chemistry, 2016, 59, 1565-1579.	2.9	82
30	Tetrazoleâ€Based Probes for Integrated Phenotypic Screening, Affinityâ€Based Proteome Profiling, and Sensitive Detection of a Cancer Biomarker. Angewandte Chemie - International Edition, 2017, 56, 15044-15048.	7.2	82
31	Benzenediol-berberine hybrids: Multifunctional agents for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2011, 19, 7228-7235.	1.4	77
32	2-Pyridinyl Î²-ketones as new ligands for room-temperature CuI-catalysed Câ€“N coupling reactions. Chemical Communications, 2009, , 1891.	2.2	74
33	Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine⁷⁹⁰ â†' Methionine⁷⁹⁰ Mutant. Journal of Medicinal Chemistry, 2012, 55, 2711-2723.	2.9	74
34	Pyrazolo[1,5-a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis. ACS Infectious Diseases, 2019, 5, 239-249.	1.8	74
35	Synthesis of Aza-Fused Polycyclic Quinolines through Copper-Catalyzed Cascade Reactions. Organic Letters, 2010, 12, 1500-1503.	2.4	71
36	Synthesis of [1,2,3]Triazolo[1,5-a]quinoxalin-4(5H)-ones through Copper-Catalyzed Tandem Reactions of N-(2-Haloaryl)propiolamides with Sodium Azide. Organic Letters, 2012, 14, 1262-1265.	2.4	71

#	Article	IF	Citations
37	Aqueous synthesis of PEGylated copper sulfide nanoparticles for photoacoustic imaging of tumors. Nanoscale, 2015, 7, 11075-11081.	2.8	68
38	Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2013, 56, 4738-4748.	2.9	67
39	MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. British Journal of Cancer, 2009, 101, 774-781.	2.9	65
40	Assembly of indole-2-carboxylic acid esters through a ligand-free copper-catalysed cascade process. Chemical Communications, 2009, , 7581.	2.2	63
41	Discovery of New Monocarbonyl Ligustrazineâ€“Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer. Journal of Medicinal Chemistry, 2016, 59, 1747-1760.	2.9	61
42	Identification of Pyrido[1,2-Î±]pyrimidine-4-ones as New Molecules Improving the Transcriptional Functions of Estrogen-Related Receptor Î±. Journal of Medicinal Chemistry, 2011, 54, 7729-7733.	2.9	60
43	Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition. Tetrahedron Letters, 2005, 46, 5949-5951.	0.7	59
44	Design and synthesis of selective degraders of EGFRL858R/T790M mutant. European Journal of Medicinal Chemistry, 2020, 192, 112199.	2.6	59
45	Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant. Journal of Medicinal Chemistry, 2013, 56, 7821-7837.	2.9	58
46	1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor Î±. Journal of Medicinal Chemistry, 2013, 56, 4631-4640.	2.9	58
47	Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. Journal of Medicinal Chemistry, 2019, 62, 2905-2915.	2.9	58
48	Small Molecule Discoidin Domain Receptor Kinase Inhibitors and Potential Medical Applications. Journal of Medicinal Chemistry, 2015, 58, 3287-3301.	2.9	57
49	Recent Progress of Synthetic Studies to Peptide and Peptidomimetic Cyclization. Current Organic Chemistry, 2008, 12, 1502-1542.	0.9	56
50	Copper-Catalyzed Tandem Reaction of Isocyanides with N-(2-Haloaryl)propiolamides for the Synthesis of Pyrrolo[3,2-c]quinolin-4-ones. Journal of Organic Chemistry, 2011, 76, 5346-5353.	1.7	56
51	Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. Journal of Medicinal Chemistry, 2020, 63, 14404-14424.	2.9	56
52	Towards an Optimized Culture Medium for the Generation of Mouse Induced Pluripotent Stem Cells. Journal of Biological Chemistry, 2010, 285, 31066-31072.	1.6	55
53	Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. Journal of Biological Chemistry, 2016, 291, 23208-23223.	1.6	53
54	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/Î²-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clinical Cancer Research, 2017, 23, 789-803.	3.2	52

#	Article	IF	Citations
55	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	5.7	52
56	Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 5911-5916.	2.9	51
57	Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. BMC Cancer, 2017, 17, 87.	1.1	48
58	Identification of New Small-Molecule Inducers of Estrogen-related Receptor Î± (ERRÎ±) Degradation. ACS Medicinal Chemistry Letters, 2019, 10, 767-772.	1.3	47
59	Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor Î± and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells. Clinical Cancer Research, 2012, 18, 1966-1978.	3.2	46
60	Discovery and optimization of 1-(1 H -indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. European Journal of Medicinal Chemistry, 2018, 147, 238-252.	2.6	46
61	Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). Journal of Medicinal Chemistry, 2018, 61, 3037-3058.	2.9	46
62	Discovery of JND3229 as a New EGFR^{C797S} Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Medicinal Chemistry Letters, 2018, 9, 1123-1127.	1.3	46
63	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 58-83.	2.9	46
64	Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Molecular Cancer, 2020, 19, 90.	7.9	44
65	2-Amino-2,3-dihydro-1H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. Journal of Medicinal Chemistry, 2019, 62, 7431-7444.	2.9	43
66	Blocking interaction between SHP2 and PDâ€1 denotes a novel opportunity for developing PDâ€1 inhibitors. EMBO Molecular Medicine, 2020, 12, e11571.	3.3	40
67	Structure-Based Design of Flavonoid Compounds As a New Class of Small-Molecule Inhibitors of the Anti-apoptotic Bcl-2 Proteins. Journal of Medicinal Chemistry, 2007, 50, 3163-3166.	2.9	39
68	New benzimidazole-2-urea derivates as tubulin inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4250-4253.	1.0	38
69	Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing Î²-Catenin Signaling. Molecular Cancer Therapeutics, 2014, 13, 1217-1230.	1.9	37
70	2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 543-548.	1.3	37
71	Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity. European Journal of Medicinal Chemistry, 2017, 125, 41-48.	2.6	37
72	A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy. Cancer Biology and Therapy, 2008, 7, 845-852.	1.5	36

#	Article	IF	Citations
73	The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression. Kidney International, 2017, 92, 612-624.	2.6	36
74	Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943. Biochemical and Biophysical Research Communications, 2017, 487, 339-343.	1.0	35
75	Visualization and Quantification of Browning Using a Ucp1-2A-Luciferase Knock-in Mouse Model. Diabetes, 2017, 66, 407-417.	0.3	35
76	Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR^{L858R/T790M/C797S}). Journal of Medicinal Chemistry, 2019, 62, 7302-7308.	2.9	35
77	Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine³¹⁵â†'Isoleucine³¹⁵ Mutant. Journal of Medicinal Chemistry, 2012, 55, 10033-10046.	2.9	34
78	Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents. ACS Medicinal Chemistry Letters, 2014, 5, 89-93.	1.3	34
79	Cellâ€•and Tissueâ€Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin. Angewandte Chemie - International Edition, 2018, 57, 9284-9289.	7.2	34
80	Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib. Journal of Medicinal Chemistry, 2014, 57, 2692-2703.	2.9	33
81	Synthesis, Skeletal Rearrangement, and Biological Activities of Spirooxindoles: Exploration of a Stepwise Câ€Piancatelli Rearrangement. European Journal of Organic Chemistry, 2014, 2014, 338-349.	1.2	33
82	GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biology and Therapy, 2010, 9, 640-650.	1.5	32
83	N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 543-547.	1.3	32
84	DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2. Oncotarget, 2015, 6, 6944-6958.	0.8	32
85	C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR^{T790M} mutant. MedChemComm, 2015, 6, 1693-1697.	3.5	31
86	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 327-332.	1.3	31
87	A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. European Journal of Medicinal Chemistry, 2017, 126, 1107-1117.	2.6	31
88	New thiazole carboxamides as potent inhibitors of Akt kinases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1208-1212.	1.0	30
89	Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2013, 56, 8803-8813.	2.9	30
90	Pyrimido[4,5â€d]pyrimidinâ€4(1H)â€one Derivatives as Selective Inhibitors of EGFR Threonine⁷⁹⁰ to Methionine⁷⁹⁰ (T790M) Mutants. Angewandte Chemie - International Edition, 2013, 52, 8387-8390.	7.2	30

#	Article	IF	Citations
91	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. Journal of Medicinal Chemistry, 2020, 63, 10726-10741.	2.9	30
92	Efficient synthesis of isoflavone analogues via a Suzuki coupling reaction. Tetrahedron Letters, 2005, 46, 3707-3709.	0.7	29
93	Small-Molecule CSF1R Inhibitors as Anticancer Agents. Current Medicinal Chemistry, 2020, 27, 3944-3966.	1.2	29
94	Synthesis of Enantiopure Î±,Î±-Disubstituted Amino Acids from the Asymmetric Strecker Reaction Products of Aldehydes. Organic Letters, 2000, 2, 2515-2517.	2.4	28
95	Rutin suppresses human-amylin/hIAPP misfolding and oligomer formation in-vitro , and ameliorates diabetes and its impacts in human-amylin/hIAPP transgenic mice. Biochemical and Biophysical Research Communications, 2017, 482, 625-631.	1.0	28
96	Synthesis of 1-Aryl-1H -indazoles via a Ligand-Free Copper- Catalyzed Intramolecular Amination Reaction. Chinese Journal of Chemistry, 2011, 29, 1199-1204.	2.6	27
97	Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea. Nature Communications, 2020, 11, 1473.	5.8	27
98	Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5916-5919.	1.0	25
99	Enantiomerically Pure Hexahydropyrazinoquinolines as Potent and Selective Dopamine 3 Subtype Receptor Ligands. Journal of Medicinal Chemistry, 2005, 48, 3171-3181.	2.9	24
100	Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors. Current Pharmaceutical Design, 2012, 18, 3421-3431.	0.9	24
101	Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells. Oncology Letters, 2016, 12, 3598-3608.	0.8	24
102	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamid as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. Journal of Medicinal Chemistry, 2018, 61, 7977-7990.	2.9	24
103	Selective Inhibition of Matrix Metalloproteinase Isozymes and in Vivo Protection against Emphysema by Substituted Î³-Keto Carboxylic Acids. Journal of Medicinal Chemistry, 2006, 49, 456-458.	2.9	23
104	Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 443-446.	1.0	23
105	Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRÎ±: roles of Mcl-1 and Î²-catenin. Molecular Cancer, 2014, 13, 17.	7.9	23
106	Structure Based Design of		

#	Article	IF	Citations
109	Minimalist linkers suitable for irreversible inhibitors in simultaneous proteome profiling, live-cell imaging and drug screening. Chemical Communications, 2019, 55, 834-837.	2.2	22
110	Applications of Activityâ€Based Protein Profiling (ABPP) and Bioimaging in Drug Discovery. Chemistry - an Asian Journal, 2020, 15, 34-41.	1.7	22
111	Design, synthesis and structureâ€“activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1701-1705.	1.0	21
112	Atovaquone derivatives as potent cytotoxic and apoptosis inducing agents. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5091-5094.	1.0	21
113	Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents. Bioorganic and Medicinal Chemistry, 2015, 23, 5144-5150.	1.4	21
114	Design, Synthesis, and Structureâ€“Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 2353-2371.	2.9	21
115	Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer. European Journal of Medicinal Chemistry, 2018, 152, 542-559.	2.6	21
116	Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). Journal of Medicinal Chemistry, 2019, 62, 5944-5978.	2.9	21
117	Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. European Journal of Medicinal Chemistry, 2019, 166, 318-327.	2.6	21
118	Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. European Journal of Medicinal Chemistry, 2014, 77, 75-83.	2.6	20
119	Affinity-Based Protein Profiling Reveals Cellular Targets of Photoreactive Anticancer Inhibitors. ACS Chemical Biology, 2019, 14, 2546-2552.	1.6	20
120	Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. Journal of Medicinal Chemistry, 2022, 65, 6840-6858.	2.9	20
121	Asymmetric synthesis of Î±,Î±-disubstituted amino acids by diastereoselective functionalization of enantiopure phenyloxazinones, derivatives of asymmetric Strecker reaction products of aldehydes. Tetrahedron, 2001, 57, 6361-6366.	1.0	19
122	Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors. European Journal of Medicinal Chemistry, 2013, 66, 82-90.	2.6	19
123	Alleviation of Podophyllotoxin Toxicity Using Coexisting Flavonoids from Dysosma versipellis. PLoS ONE, 2013, 8, e72099.	1.1	19
124	GZD856, a novel potent PDGFRÎ±/Î² inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer Letters, 2016, 375, 172-178.	3.2	19
125	Design, Synthesis, and Structureâ€“Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-Î± Motif Kinase (ZAK) Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 2114-2130.	2.9	19
126	LSâ€106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Science, 2022, 113, 709-720.	1.7	19

#	Article	IF	Citations
127	2-Oxo-3, 4-dihydropyrimido[4, 5- d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry, 2017, 135, 531-543.	2.6	18
128	Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. ACS Medicinal Chemistry Letters, 2019, 10, 1180-1186.	1.3	18
129	Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. Journal of Medicinal Chemistry, 2019, 62, 8951-8952.	2.9	18
130	Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents. ACS Medicinal Chemistry Letters, 2019, 10, 295-299.	1.3	18
131	Hybrid compounds as new Bcr/Abl inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1965-1968.	1.0	17
132	Harmine Induces Adipocyte Thermogenesis through RAC1-MEK-ERK-CHD4 Axis. Scientific Reports, 2016, 6, 36382.	1.6	17
133	Design, synthesis, and Structureâ€“Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors. European Journal of Medicinal Chemistry, 2020, 203, 112552.	2.6	17
134	<scp>I</scp>-Proline-Promoted Rosenmund-von Braun Reaction. Synlett, 2008, 2008, 69-72.	1.0	16
135	Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790â†' methionine790 mutant. MedChemComm, 2012, 3, 1155.	3.5	16
136	Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors. European Journal of Medicinal Chemistry, 2019, 179, 470-482.	2.6	16
137	Development and application of novel electrophilic warheads in target identification and drug discovery. Biochemical Pharmacology, 2021, 190, 114636.	2.0	16
138	GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. Oncotarget, 2017, 8, 87002-87015.	0.8	16
139	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. Journal of Medicinal Chemistry, 2022, 65, 1735-1748.	2.9	16
140	Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Cancer Letters, 2014, 353, 115-123.	3.2	15
141	The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation. Bioorganic and Medicinal Chemistry, 2016, 24, 4310-4317.	1.4	15
142	Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer. Chemical Communications, 2019, 55, 1596-1599.	2.2	15
143	Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. European Journal of Medicinal Chemistry, 2021, 211, 113023.	2.6	15
144	A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells. Annals of Hematology, 2007, 86, 471-481.	0.8	14

#	Article	IF	Citations
145	Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer. ACS Medicinal Chemistry Letters, 2018, 9, 262-267.	1.3	14
146	Manganeseâ€Catalyzed Câ^'H Annulation of Ketimines with Allenes: Stereoselective Synthesis of 1â€Aminoindanes. Advanced Synthesis and Catalysis, 2018, 360, 2952-2958.	2.1	14
147	GZD824 as a FLT3, FGFR1 and PDGFRÎ± Inhibitor Against Leukemia In Vitro and In Vivo. Translational Oncology, 2020, 13, 100766.	1.7	14
148	Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharmaceutica Sinica B, 2021, 11, 1315-1328.	5.7	14
149	Pharmacophore and Molecular Docking Guided 3D-QSAR Study of Bacterial Enoyl-ACP Reductase (FabI) Inhibitors. International Journal of Molecular Sciences, 2012, 13, 6620-6638.	1.8	13
150	Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3458-3463.	1.0	13
151	Tetrazoleâ€Based Probes for Integrated Phenotypic Screening, Affinityâ€Based Proteome Profiling, and Sensitive Detection of a Cancer Biomarker. Angewandte Chemie, 2017, 129, 15240-15244.	1.6	13
152	A novel reactive turn-on probe capable of selective profiling and no-wash imaging of Bruton's tyrosine kinase in live cells. Chemical Communications, 2019, 55, 3473-3476.	2.2	13
153	Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. Journal of Medicinal Chemistry, 2022, 65, 6325-6337.	2.9	13
154	1-Benzyl-4-phenyl-1H-1,2,3-triazoles improve the transcriptional functions of estrogen-related receptor Î³ and promote the browning of white adipose. Bioorganic and Medicinal Chemistry, 2015, 23, 3751-3760.	1.4	12
155	GZD824 overcomes FGFR1â€V561F/M mutant resistance in vitro and in vivo. Cancer Medicine, 2021, 10, 4874-4884.	1.3	12
156	A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton. Investigational New Drugs, 2012, 30, 490-507.	1.2	11
157	Rational Design and Structure Validation of a Novel Peptide Inhibitor of the Adenomatous-Polyposis-Coli (APC)â€"Rho-Guanine-Nucleotide-Exchange-Factor-4 (Asef) Interaction. Journal of Medicinal Chemistry, 2018, 61, 8017-8028.	2.9	11
158	Design and Optimization of 3â€²-(Imidazo[1,2-a]pyrazin-3-yl)-[1,1â€²-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 379-384.	1.3	11
159	A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 341-350.	2.4	11
160	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Brutonâ€™s tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3052-3059.	1.0	10
161	Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R. Acta Pharmacologica Sinica, 2018, 39, 1768-1776.	2.8	10
162	Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Letters, 2020, 472, 132-141.	3.2	10

#	Article	IF	Citations
163	Quantitative Proteomics Reveals Cellular Off-Targets of a DDR1 Inhibitor. ACS Medicinal Chemistry Letters, 2020, 11, 535-540.	1.3	10
164	Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by â€œInverse Drug Discoveryâ€• Journal of Medicinal Chemistry, 2021, 64, 15582-15592.	2.9	10
165	Structureâ€“activity study on a series of Î±-glutamic acid scaffold based compounds as new ADAMTS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4457-4461.	1.0	9
166	Detection of Epsteinâ€“Barr virus infection in cancer by using highly specific nanoprobe based on dBSA capped CdTe quantum dots. RSC Advances, 2014, 4, 22545.	1.7	9
167	Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 647-652.	1.3	9
168	BMS309403 Stimulates Glucose Uptake in Myotubes through Activation of AMP-Activated Protein Kinase. PLoS ONE, 2012, 7, e44570.	1.1	9
169	Direct Oxidation of Nâ€Benzylamides to Aldehydes or Ketones by Nâ€Bromosuccinimide. Synthetic Communications, 2008, 38, 1629-1637.	1.1	8
170	Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death and Disease, 2014, 5, e1114-e1114.	2.7	8
171	Copperâ€Mediated Diamination of Arylboronic Acids for the Synthesis of 2â€Aryl Benzimidazoles Using Trimethylsilyl Azide as the Amino Sources with Aldehydes. Advanced Synthesis and Catalysis, 2020, 362, 3442-3446.	2.1	8
172	Glucocappasalin Induces G2/M-Phase Arrest, Apoptosis, and Autophagy Pathways by Targeting CDK1 and PLK1 in Cervical Carcinoma Cells. Frontiers in Pharmacology, 2021, 12, 671138.	1.6	8
173	Secondary-structure switch regulates the substrate binding of a YopJ family acetyltransferase. Nature Communications, 2021, 12, 5969.	5.8	8
174	Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR^{T790M/C797S} Mutants. ACS Medicinal Chemistry Letters, 2022, 13, 196-202.	1.3	8
175	Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders. Journal of Medicinal Chemistry, 2022, 65, 2313-2328.	2.9	8
176	DC120, a Novel and Potent Inhibitor of AKT Kinase, Induces Tumor Cell Apoptosis and Suppresses Tumor Growth. Molecular Pharmacology, 2012, 82, 189-198.	1.0	7
177	Design and synthesis of N -(4-aminopyridin-2-yl)amides as B-Raf V600E inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2760-2763.	1.0	7
178	Cellâ€and Tissueâ€Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin. Angewandte Chemie, 2018, 130, 9428-9433.	1.6	7
179	Cellâ€and Tissueâ€Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor. Chemistry - an Asian Journal, 2018, 13, 2601-2605.	1.7	7
180	Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRÎ±-expressing cells. Oncotarget, 2014, 5, 10407-10420.	0.8	7

#	Article	IF	Citations
181	Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies. European Journal of Medicinal Chemistry, 2022, 228, 114022.	2.6	7
182	An efficient synthesis of optically pure (S)-2-functionalized 1,2,3,4-tetrahydroquinoline. Tetrahedron Letters, 2004, 45, 1027-1029.	0.7	6
183	Copper(I) Iodide Catalyzed Domino Process to Quinazolin-4(3H)-ones. Synthesis, 2008, 2008, 3974-3980.	1.2	6
184	Copper(I) Iodide Catalyzed Synthesis of Quinolinones via Cascade Reactions of 2-Halobenzocarbonyls with 2-Arylacetamides. Synthesis, 2011, 2011, 1547-1554.	1.2	6
185	Novel Anaplastic Lymphoma Kinase Inhibitors Targeting Clinically Acquired Resistance. Journal of Medicinal Chemistry, 2014, 57, 1167-1169.	2.9	6
186	Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl^{T315I} inhibitor overcoming acquired imatinib resistance. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 331-336.	2.5	6
187	Crenolanibâ€Derived Probes Suitable for Cellâ€and Tissueâ€Based Protein Profiling and Singleâ€Cell Imaging. ChemBioChem, 2019, 20, 1783-1788.	1.3	6
188	Leucine-zipper and Sterile-Î± Motif Kinase (ZAK): A Potential Target for Drug Discovery. Current Medicinal Chemistry, 2016, 23, 3801-3812.	1.2	6
189	Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design. Bioorganic and Medicinal Chemistry, 2021, 50, 116457.	1.4	6
190	Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 3249-3265.	2.9	6
191	Room-Temperature Debenzylation of N-Benzylcarboxamides by N-Bromosuccinimide. Synthesis, 2007, 2007, 3129-3134.	1.2	5
192	Targeted inhibition of ZAK ameliorates renal interstitial fibrosis. Translational Research, 2022, 246, 49-65.	2.2	5
193	Mild Conditions for Copper-Catalyzed N-Arylation of Imidazoles. Synthesis, 2010, 2010, 1505-1511.	1.2	4
194	Synthesis of 4-Oxoindeno[1,2-b]pyrroles through Copper-Catalyzed Tandem Reactions of 1-(2-Haloaryl)enones with Isocyanides. Synthesis, 2011, 2011, 3037-3044.	1.2	4
195	Novel conjugates of endoperoxide and 4-anilinoquinazoline as potential anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1341-1345.	1.0	4
196	GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. Journal of Drug Targeting, 2019, 27, 442-450.	2.1	4
197	Discovery of JND003 as a New Selective Estrogen-Related Receptor Î± Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance. ACS Bio & Med Chem Au, 2022, 2, 282-296.	1.7	4
198	The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. RSC Medicinal Chemistry, 2020, 11, 293-296.	1.7	3

#	Article	IF	Citations
199	A novel photocaged B-RafV600E inhibitor toward precise melanoma treatment. Bioorganic and Medicinal Chemistry Letters, 2022, 64, 128683.	1.0	3
200	An Efficient Synthesis of ABT-263, a Novel Inhibitor of Antiapoptotic Bcl-2 Proteins. Synthesis, 2008, 2008, 2398-2404.	1.2	2
201	Quantitative data describing the impact of the flavonol rutin on in-vivo blood-glucose and fluid-intake profiles, and survival of human-amylin transgenic mice. Data in Brief, 2017, 10, 298-303.	0.5	2
202	YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR^{L858R, T790M}â€mutant resistance in vitro and in vivo. Cancer Medicine, 2018, 7, 1430-1439.	1.3	2
203	Allosterische Kinaseinhibitoren â€“ Erwartungen und Chancen. Angewandte Chemie, 2020, 132, 13868-13881.	1.6	2
204	Proteome-wide Identification of Off-Targets of a Potent EGFR^{L858R/T790M} Mutant Inhibitor. ACS Medicinal Chemistry Letters, 2022, 13, 292-297.	1.3	2
205	A Room-Temperature, Copper-Catalyzed Cascade Process for Diethyl 2-Aryl-3,4-dihydro-4-oxo-1,1(2H)-naphthalenedicarboxylate. Synthesis, 2010, 2010, 3289-3294.	1.2	1
206	Sequential Hydration-Condensation-Double Cyclization of Pyridine-Substituted 2-Alkynylanilines: An Efficient Approach to Quinoline-Based Heterocycles. Synthesis, 2011, 2011, 1723-1732.	1.2	1
207	Mild Conditions for Copper-Catalyzed N-Arylation of Imidazoles. Synthesis, 2011, 2011, 2684-2684.	1.2	1
208	Overexpression of ZAKÎ² in human osteosarcoma cells enhances ZAKÎ± expression, resulting in a synergistic apoptotic effect. Cell Biochemistry and Function, 2018, 36, 176-182.	1.4	1
209	Two-photon fluorescent turn-on probes for highly efficient detection and profiling of thiols in live cells and tissues. Biological Chemistry, 2021, .	1.2	1
210	Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor. Frontiers in Oncology, 2021, 11, 807200.	1.3	1
211	Design, Synthesis and Structureâ€"Activity Relationship Studies of Hexahydropyrazinoquinolines as a Novel Class of Potent and Selective Dopamine Receptor 3 (D3) Ligands.. ChemInform, 2005, 36, no.	0.1	0
212	Efficient Synthesis of Isoflavone Analogues via a Suzuki Coupling Reaction.. ChemInform, 2005, 36, no.	0.1	0
213	Synthesis of Spirooxindoles via Asymmetric 1,3-Dipolar Cycloaddition.. ChemInform, 2005, 36, no.	0.1	0
214	Identification of Niclosamide as a New Lead Compound to Suppress the Metastasis of Prostate Cancer Cells. , 2014, 4, .		0
215	Super-stable centimetre-scale inverse opal belts integrated with CdTe QDs for narrow band fluorescence optical waveguiding. Journal of Materials Chemistry C, 2015, 3, 10964-10967.	2.7	0
216	Small Molecule Inhibitors of Discoidin Domain Receptors (DDRs). , 2016, , 181-200.		0

#	Article	IF	Citations
217	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	2.9	0
218	Pan-cancer Analysis of CENPA as a Potential Prognostic and Immunological Biomarker in Human Cancer. Current Bioinformatics, 2022, 17, .	0.7	0